Biology:VBI-2902
From HandWiki
Revision as of 22:16, 21 October 2021 by imported>WikiEd2 (over-write)
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | vlp |
| Clinical data | |
| Routes of administration | Intramuscular |
VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies.
Development
In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[1] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[1] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[1] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[2] The company's CEO, Jeff Baxter, said that VBI-2902 is cheaper to produce than other vaccines.
References
- ↑ 1.0 1.1 1.2 "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines. March 9, 2021. https://www.vbivaccines.com/press-releases/enrollment-in-phase-1-2-covid-study/.
- ↑ "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. August 2020. Retrieved March 22, 2021.
External links
 |
